- In July 2026, Bristol Myers Squibb announced that the FDA accepted its New Drug Application for mezigdomide in combination with carfilzomib and dexamethasone to treat relapsed or refractory multiple myeloma, backed by Phase 3 data showing a clinically meaningful improvement in progression-free survival versus standard of care.
- An interesting aspect of this update is that the SUCCESSOR-2 trial enrolled a heavily pretreated, mostly triple-class-exposed patient population, highlighting potential relevance for difficult-to-treat multiple myeloma cases and reinforcing the importance of cereblon E3 ligase modulators in BMS’s hematology portfolio.
- We’ll now examine how the Phase 3 progression-free survival benefit for MeziKd could influence Bristol Myers Squibb’s broader investment narrative.
The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
Bristol-Myers Squibb Investment Narrative Recap
To own Bristol Myers Squibb, you need to believe its late stage pipeline can meaningfully soften upcoming patent cliffs and pricing pressure, while supporting the dividend. The MeziKd Phase 3 data and FDA filing highlight progress in hematology, but do not change that the key near term catalyst is execution on multiple upcoming launches and label expansions, and the biggest current risk remains revenue erosion as Eliquis and Opdivo lose exclusivity.
Among recent announcements, the expansion of the BioNTech radiopharmaceutical collaboration and broader oncology program stands out next to mezigdomide. Both underline how BMS is leaning on external innovation plus internal CELMoD expertise to build a deeper oncology portfolio that can help offset losses from aging blockbusters. For investors watching the patent cliff, the combination of MeziKd’s data and these partnered assets forms an important part of the near term pipeline story.
Yet against this promising multiple myeloma update, investors should also be aware of how concentrated the current portfolio still is...
Read the full narrative on Bristol-Myers Squibb (it's free!)
Bristol-Myers Squibb's narrative projects $40.1 billion revenue and $8.6 billion earnings by 2029. This requires a 6.2% yearly revenue decline and about a $1.3 billion earnings increase from $7.3 billion today.
Uncover how Bristol-Myers Squibb's forecasts yield a $62.96 fair value, a 4% upside to its current price.
Exploring Other Perspectives
While MeziKd’s progress could eventually support the pipeline, the most pessimistic analysts were still assuming revenues might fall to about US$37.4 billion and earnings to roughly US$8.1 billion, so it is worth seeing how views like that could shift if the data translate into approvals.
Explore 8 other fair value estimates on Bristol-Myers Squibb - why the stock might be worth over 2x more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Bristol-Myers Squibb research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Bristol-Myers Squibb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bristol-Myers Squibb's overall financial health at a glance.
Interested In Other Possibilities?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
- Capitalize on the AI infrastructure supercycle with our selection of the 54 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com